Market News & Trends
Eyenovia Announces Positive Study Results Demonstrating its Optejet Delivery Technology Reduces Conjunctival Cell Toxicity From Preserved Ophthalmic Solutions to a Level Comparable With Non-Preserved Solutions
Eyenovia, Inc. recently announced positive results from a research study conducted in collaboration with Dr. Pedram Hamrah, Interim Chairman of Ophthalmology at Tufts Medical Center, which evaluated the ocular surface….
BioIntelliSense Launches New BioButton Rechargeable Wearable Device for Continuous Medical-Grade Monitoring of 20+ Vital Signs & Biometrics
BioIntelliSense recently expanded its commitment to creating a new standard of remote patient care with the commercial launch of its medical-grade BioButton Rechargeable wearable device.…
OncoArendi Therapeutics Announces License Option Agreement With University of Michigan
OncoArendi Therapeutics S.A. recently announced it has entered into an option-to-license agreement with Innovation Partnerships at the University of Michigan (U-M) to develop novel small…
NeuBase Therapeutics Presents New Preclinical Data for its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution & Myotonia Reversal
NeuBase Therapeutics, Inc. recently announced new preclinical data for its lead development candidate, NT-0231.F, to treat myotonic dystrophy type 1 (DM1). ….
Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis
Phathom Pharmaceuticals, Inc. recently announced it has submitted a new drug application (NDA) to the US FDA for the use of vonoprazan as a treatment…
Oxford Biomedica Broadens its Viral Vector Capabilities With the Launch of Oxford Biomedica Solutions
Oxford Biomedica plc recently announced it has completed its deal with Homology Medicines Inc. to establish Oxford Biomedica Solutions LLC, a new US-based full scope,…
Synthetic Biologics Completes Acquisition of VCN Biosciences
Synthetic Biologics, Inc. recently announced it has completed the acquisition of VCN Biosciences, S.L. (VCN) following the satisfaction of all closing conditions…..
Vetter’s Extraordinary Performance Sweeps the Board at the 2022 CMO Leadership Awards
Vetter recently announced it has won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service…..
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study
Cocrystal Pharma, Inc. recently announced dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered…
Pharmazz Announces FDA Clearance of an IND Application for Phase 2 Clinical Trial
Pharmazz recently announced US FDA clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of centhaquine as an adjuvant to…
Evonik Launches New Technology to Improve Solubility of Oral Small Molecules
Evonik recently announced it now offers EUDRATEC SoluFlow, a new microparticle technology to enhance solubility of active pharmaceutical ingredients in oral drug products…..
Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial
Denali Therapeutics Inc. recently announced dosing has begun in a Phase 1/2 clinical trial of DNL593 (PTV:PGRN) for the potential treatment of frontotemporal dementia (FTD)…
Vibalogics Completes Major Milestone in $50-Million Facility Expansion
Vibalogics has recently announced the completion of its expansion project at its GMP facility in Cuxhaven, Germany. The new building features biosafety level (BSL) 2…
Novartis, Voyager Therapeutics Reach License Option Agreement
Novartis recently announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three….
Adaptive Research & UBERDOC Announce Collaboration
Adaptive Research and UBERDOC recently announced a collaboration to expand clinical trial access to the physicians and clinical trial sites….
BioNTech & Regeneron Expand Strategic Collaboration
BioNTech SE recently announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor….
Atossa Therapeutics Announces Issuance of Key US Patent Covering Endoxifen
Atossa Therapeutics, Inc. recently announced the US Patent and Trademark office has issued a new patent further strengthening Atossa’s intellectual property in its proprietary therapy…
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. The positive final analysis included…
DNAnexus Secures $200-Million Funding to Advance its Biomedical Data-Driven Technology Platform for Precision Medicine
DNAnexus, Inc. recently announced a $200-million financing round to accelerate the global adoption of its technology, translating the world’s complex multi-omics and clinical data into…
Enteris BioPharma Publishes White Paper on Best Practices for Ensuring Content Uniformity in Solid Oral Dosage Manufacturing With HPAPI
Enteris BioPharma, Inc. recently announced the publication of a new white paper, titled HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity. The…